Cargando…
A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
BACKGROUND: Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES: Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473004/ https://www.ncbi.nlm.nih.gov/pubmed/37548637 http://dx.doi.org/10.1111/jvim.16828 |
_version_ | 1785100187899789312 |
---|---|
author | Pazzi, Paolo Fosgate, Geoffrey T. Rixon, Anouska Hanekom, Josef Kristensen, Annemarie T. Goddard, Amelia |
author_facet | Pazzi, Paolo Fosgate, Geoffrey T. Rixon, Anouska Hanekom, Josef Kristensen, Annemarie T. Goddard, Amelia |
author_sort | Pazzi, Paolo |
collection | PubMed |
description | BACKGROUND: Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES: Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or sarcomas; estimate predictive values of hemostatic variables for thromboembolic disease in tumor‐bearing dogs. ANIMALS: Thirty‐two dogs with sarcoma, 30 with carcinoma, 20 healthy age‐controlled dogs. METHODS: Prospective cross‐sectional study. A hemostasis panel (platelet concentration, thromboelastography, fibrinogen and D‐dimer concentration, factor X, VII and antithrombin activity) was performed in all dogs. Tumor‐bearing dogs underwent complete post mortem and histopathological evaluation. Comparisons between healthy dogs and tumor‐bearing dogs with and without intracavitary hemorrhage; and tumor‐bearing dogs with and without microthrombi were analyzed. RESULTS: Thromboembolic disease was identified in 32/62 (52%, 95% CI: 39%‐65%) tumor‐bearing dogs. Microthrombi were identified in 31/62 (50%, 95% CI: 37%‐63%) dogs, 21/31 (68%, 95% CI: 49%‐83%) had exclusively intra‐tumoral microthrombi, 10/31 (32%, 95% CI: 17%‐51%) had distant microthrombi. Macrothrombi were identified in 3 tumor‐bearing dogs. Hemostatic changes potentially consistent with overt and non‐overt disseminated intravascular coagulation were identified in some tumor‐bearing dogs. D‐dimer concentrations were significantly higher (P = .02) and platelet concentration significantly lower (P = .03) in tumor‐bearing dogs with microthrombi compared to tumor‐bearing dogs without microthrombi. D‐dimer concentration above 500 ng/mL was 80% sensitive and 41% specific for the prediction of microthrombi presence. CONCLUSION: The high microthrombi prevalence and concomitant hemostatic dysfunction in dogs with carcinomas or sarcomas has not previously been reported, though the clinical importance is unknown. Increased D‐dimer concentration might increase suspicion of microthrombi. |
format | Online Article Text |
id | pubmed-10473004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104730042023-09-02 A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma Pazzi, Paolo Fosgate, Geoffrey T. Rixon, Anouska Hanekom, Josef Kristensen, Annemarie T. Goddard, Amelia J Vet Intern Med SMALL ANIMAL BACKGROUND: Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES: Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or sarcomas; estimate predictive values of hemostatic variables for thromboembolic disease in tumor‐bearing dogs. ANIMALS: Thirty‐two dogs with sarcoma, 30 with carcinoma, 20 healthy age‐controlled dogs. METHODS: Prospective cross‐sectional study. A hemostasis panel (platelet concentration, thromboelastography, fibrinogen and D‐dimer concentration, factor X, VII and antithrombin activity) was performed in all dogs. Tumor‐bearing dogs underwent complete post mortem and histopathological evaluation. Comparisons between healthy dogs and tumor‐bearing dogs with and without intracavitary hemorrhage; and tumor‐bearing dogs with and without microthrombi were analyzed. RESULTS: Thromboembolic disease was identified in 32/62 (52%, 95% CI: 39%‐65%) tumor‐bearing dogs. Microthrombi were identified in 31/62 (50%, 95% CI: 37%‐63%) dogs, 21/31 (68%, 95% CI: 49%‐83%) had exclusively intra‐tumoral microthrombi, 10/31 (32%, 95% CI: 17%‐51%) had distant microthrombi. Macrothrombi were identified in 3 tumor‐bearing dogs. Hemostatic changes potentially consistent with overt and non‐overt disseminated intravascular coagulation were identified in some tumor‐bearing dogs. D‐dimer concentrations were significantly higher (P = .02) and platelet concentration significantly lower (P = .03) in tumor‐bearing dogs with microthrombi compared to tumor‐bearing dogs without microthrombi. D‐dimer concentration above 500 ng/mL was 80% sensitive and 41% specific for the prediction of microthrombi presence. CONCLUSION: The high microthrombi prevalence and concomitant hemostatic dysfunction in dogs with carcinomas or sarcomas has not previously been reported, though the clinical importance is unknown. Increased D‐dimer concentration might increase suspicion of microthrombi. John Wiley & Sons, Inc. 2023-08-07 /pmc/articles/PMC10473004/ /pubmed/37548637 http://dx.doi.org/10.1111/jvim.16828 Text en © 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | SMALL ANIMAL Pazzi, Paolo Fosgate, Geoffrey T. Rixon, Anouska Hanekom, Josef Kristensen, Annemarie T. Goddard, Amelia A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
title | A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
title_full | A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
title_fullStr | A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
title_full_unstemmed | A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
title_short | A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
title_sort | prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma |
topic | SMALL ANIMAL |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473004/ https://www.ncbi.nlm.nih.gov/pubmed/37548637 http://dx.doi.org/10.1111/jvim.16828 |
work_keys_str_mv | AT pazzipaolo aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT fosgategeoffreyt aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT rixonanouska aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT hanekomjosef aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT kristensenannemariet aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT goddardamelia aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT pazzipaolo prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT fosgategeoffreyt prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT rixonanouska prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT hanekomjosef prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT kristensenannemariet prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma AT goddardamelia prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma |